• Explore /
  • Poster
  • / Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.

Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.

Abstract Poster

Authors

null

Mayer N. Fishman

Moffitt Cancer Center, Tampa, FL

Mayer N. Fishman , Joseph I Clark , Ajjai Shivaram Alva , Brendan D. Curti , Neeraj Agarwal , Ralph J. Hauke , Kathleen Margaret Mahoney , Helen Moon , Jonathan Treisman , Scott Tykodi , Gregory A. Daniels , Michael Morse , Michael K.K. Wong , Howard Kaufman , Nancy C. Gregory , Janice P. Dutcher

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4578)

DOI

10.1200/JCO.2018.36.15_suppl.4578

Abstract #

4578

Poster Bd #

404

Abstract Disclosures

Similar Posters

First Author: Leonard Joseph Appleman

First Author: Julia Anne Batten

Poster

2014 Genitourinary Cancers Symposium

Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC).

Clinical benefit (CB) of high-dose interleukin-2 (HD IL-2) in clear cell (cc) metastatic renal cell carcinoma (mRCC).

First Author: Neeraj Agarwal

First Author: Hyejee Ohm